News by subject: TRI

Amendola, a nationally recognized, award-winning healthcare technology and life sciences public relations and marketing firm, announced that it has been selected by Lindus Health, an "anti-CRO" running radically faster, more reliable clinical trials...

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, will be presenting preclinical data on its next-generation anti-CD20 antibody, NAV-006, and ICAM-1 refractory antibody-drug...

WCG, the global leader in providing solutions that measurably improve the quality and efficiency of clinical research, today launched Total Feasibility, a new application on WCG's powerful ClinSpheretm technology platform that transforms the site...

IRBM, a leader in the field of drug discovery, announced today that it will be disclosing new data on two of its most promising internal assets at the upcoming American Association for Cancer Research (AACR) Annual Meeting occurring in San Diego,...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a burgeoning global health concern, posing a significant threat to public health and escalating the burden on healthcare resources. Characterized by the accumulation of fat in the...

Esteemed Board-Certified Plastic Surgeon, Dr. Adam J. Rubinstein, has been honored with the 2024 Aesthetic and Anti-Aging Medicine World Congress (AMWC) Best Surgical Body Shaping Award for his exceptional work in total body and breast makeover...

In this free webinar, learn how to operationalize clinical research within new-to-research communities while ensuring patient engagement and education. Attendees will learn what challenges clinical trial participants face and how sites can address...

Microbion Corporation today announced that the company has published results from its topical pravibismane...

Rigel Pharmaceuticals, Inc. today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis...

Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage biotechnology company advancing RNA immunotherapies to conquer cancer, announced...

The positive three-year follow-up results of the PHERGain clinical trial, sponsored by MEDSIR, demonstrating that one-third of patients with localized HER2-positive breast cancer can be cured without the need for chemotherapy, have been published in...

UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug...

ProfoundBio, a clinical-stage biotechnology company dedicated to developing novel antibody-drug conjugate (ADC) therapies for patients with cancer, today announced its participation at the upcoming American Association for Cancer Research (AACR)...

myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with brainstrust, a UK-based charity that helps people living...

Johnson & Johnson announced today that clinical and real-world evidence from its cardiovascular portfolio will be featured at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) taking place April 6-8, 2024, in Atlanta,...

To foster the next generation of life science research, 59 of the world's top emerging scientists from 28 nations have won 2024 Human Frontier Science Program (HFSP) Fellowships. "Brilliance is not born, it has to be cultivated," said HFSP Chief...

Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a study exhibiting the safety and efficacy of Wharton's Jelly connective tissue allograft for rotator cuff tears. The need for further research in supplementing...

IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercialising innovative cell therapy and antibody products, is pleased to announce that the Investigational New Drug (IND)...

Partner Therapeutics, Inc. (PTx) announced that its partner Nobelpharma received approval from the Japanese Pharmaceuticals and Medical Device Agency (PMDA) for the inhaled use of Leukine (sargramostim), branded in Japan as Sargmalin, to treat aPAP....

Today, the U.S. Food and Drug Administration approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective...

The Children's Heart Foundation is proud to introduce the inaugural Underrepresented Minority in Medicine Research Training Award (URMRTA), an initiative aimed at supporting the career development of underrepresented minority individuals in pediatric...

Monteris Medical announced today that a study on laser interstitial thermal therapy (LITT) for patients with meningioma, the most commonly diagnosed primary brain tumor, was published in the March 8 issue of Journal of Neurosurgery. This analysis of...

Reaction Biology ("Reaction" or the "Company"), an industry-leading provider of drug discovery and development services, today announced that it will feature its recently launched HotSpottm...

Cohere Health, a recognized leader in clinical intelligence and prior authorization automation, today announced a new capability to enhance payer-provider collaboration via Epic's Payer Platform....

Nine million Americans have scoliosis; 90% of which presents during adolescence. A new clinical trial* demonstrates the efficacy of a unique, non-surgical treatment that quickly reduces curves that can become disabling. Lengthy, uncomfortable bracing...

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that through its collaboration agreement with a...

Inspiratm Technologies OXY B.H.N. Ltd. (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRAtm ART100 Device for an artificial...

Neurocrine Biosciences, Inc. today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive...

In this free webinar, a former oncology clinical trial participant and cancer survivor?who is also a pharmaceutical R&D leader?will share some of her experiences as a clinical trial participant, including the impact of technology. She and other...

Harmony Biosciences Holdings, Inc. ("Harmony") has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate the safety and efficacy of pitolisant as a treatment for excessive daytime sleepiness (EDS) and behavioral symptoms in...

BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys" or "Company") announced that it has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a Patent ("Patent") for inducing an antibody immune response from a...

Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its biomarker?guided Phase 2b clinical trial (ENLIGHTEN) designed to assess the efficacy and safety...

Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has submitted an Investigational New Drug (IND) application to the U.S....

Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics, achieved a major milestone today with the first patient dosed in its First-in-human phase I clinical trial for RAG-01 conducted in collaboration with GenesisCare,...

SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases including cystic fibrosis (CF), muco-obstructive diseases like COPD, asthma, non-CF bronchiectasis (NCFB) and...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received agreement from...

Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announces it will be exhibiting at the American Association for Cancer Research (AACR)...

Bio-Techne Corporation today announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR),...

Filament Health Corp. (NEO: FH) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, will be participating in the Water Tower Research Fireside Chat Series on April 4, 2024, at 12:00 pm ET....

TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway$31 million...

Prelude Corporation (PreludeDxtm), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that data will be highlighted in a Quickshot Scientific Session and poster presentation at the 25th American...

Cepheid today announced that Xpert® HIV-1 Qual XC has been awarded World Health Organization (WHO) prequalification. Inclusion on the prequalification list signifies that Xpert HIV-1 Qual XC meets WHO's stringent performance, quality, safety and...

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42. After thorough analysis of the Phase II trial data of ASC42 for primary biliary cholangitis (PBC) (ClinicalTrials.gov:...

SimBioSys, a leading innovator in precision oncology, and General Inception ("GI"), a global company Igniter, today announce a strategic partnership that aims to significantly reduce oncology drug...

RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, obtained Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) recently for its innovative BLyS/APRIL...

Vanda Pharmaceuticals Inc. (Vanda) today announced that the U.S. Food and Drug Administration (FDA) has approved Fanapt® (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I...

Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a...

ViaLase, Inc., a clinical stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it will present clinical data as well as provide a business and technology overview...

Hoag is the first site in the world to enroll patients in two clinical trials for prostate cancer staging and treatment. One trial focuses on molecular imaging and the other on molecular therapy; both are poised to redefine the standard of care for...

EpicentRx, Inc, a clinical-stage biotechnology drug and device company with two therapeutic platforms that address cancer and inflammatory diseases of unmet clinical need, today announced that an abstract on its lead therapy, AdAPT-001, will be...